MARKET

TYME

TYME

Tyme Tech
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.8700
-0.0440
-4.81%
Opening 11:44 10/30 EDT
OPEN
0.9045
PREV CLOSE
0.9140
HIGH
0.9100
LOW
0.8700
VOLUME
34.44K
TURNOVER
--
52 WEEK HIGH
2.040
52 WEEK LOW
0.8601
MARKET CAP
110.39M
P/E (TTM)
-3.7100
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Tyme Technologies to Present at Jefferies Virtual Global Healthcare Conference on November 17-19, 2020
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Jefferies Virtual Global Healthcare Conference on November 17-19. In one-on-one sessions, the Company will present its corporate overview for fiscal year 2021 with a special focus on multiple growth opportunities driven by advances in the science of cancer cell metabolism, SM-88 (racemetyrosine) late-stage trials in pancreatic cancer, SM-88 HopES trial in ultra-rare metastatic sarcoma, proof-of-concept RESPOnD™ trial evaluating TYME-19 in COVID-19, and expanding clinical plans for its cancer-metabolism pipeline candidate SM-88 in prostate, breast and hematological cancers.
Business Wire · 10/13 12:00
TYME Technologies: My Bamboo Speculation In A Potential Leader In Cancer Metabolism-Based Therapies.
I am taking a "Bamboo Investment" approach to Tyme Technologies in anticipation the company's pivotal trial data will confirm SM-88's ability to be a game changing oncology agent.Tyme is matching SM-88 up against pancreatic cancer in the 2nd and 3rd lines of treatment. If approved, SM-88 will be the first FDA approved product for 3rd-line treatment.TYME-18 has impressive preclinical data showing 11 of 12 mice showing complete responses to their treatment. Now, we wait to see what route Tyme will pick for TYME-18's IND.I discuss my leading near-term downside risk and why I am looking to employ a bamboo approach to TYME.
Seekingalpha · 10/08 16:59
Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism
Tyme has a solid product candidate in pancreatic cancer.The company has no debt, strong IP, good insider interest.Current price is a little on the higher side for my comfort.This article was posted for TPT subscribers earlier this month.
Seekingalpha · 09/23 16:14
Is Tyme Technologies, Inc.'s (NASDAQ:TYME) Shareholder Ownership Skewed Towards Insiders?
The big shareholder groups in Tyme Technologies, Inc. (NASDAQ:TYME) have power over the company. Insiders often own a...
Simply Wall St. · 09/16 19:05
TYMEs Phase II Prostate Cancer Study Evaluating SM-88 in Patients with Non-Metastatic Recurrent Prostate Cancer Published in the Journal, Investigational New Drugs
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced that the final results of its SM-88 Phase II Prostate Cancer study designed to evaluate the safety, tolerability and efficacy of SM-88 in patients with non-metastatic
Business Wire · 09/15 13:00
Tyme Technologies to Present at BioNJs 10th Annual BioPartnering Conference on October 6, 2020
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership team will present at the BioNJ 10th Annual BioPartnering Conference on Tuesday, October 6, 2020. The Company will present its corporate overview
Business Wire · 09/14 13:00
Tyme Technologies to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that its leadership will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 22, 2020. The Company will present its corporate overview
Business Wire · 09/09 12:00
Tyme Technologies offers 2.2M shares for sale
Tyme Technologies ([[TYME]] -2.4%) announces offer and sale of up to 2.17M common shares, issuable upon the exercise of the warrants at an exercise price of $1.80 per share, expiring on
Seekingalpha · 09/03 14:09
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TYME. Analyze the recent business situations of Tyme Tech through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TYME stock price target is 8.17 with a high estimate of 9.50 and a low estimate of 7.00.
EPS
Institutional Holdings
Institutions: 100
Institutional Holdings: 19.74M
% Owned: 15.56%
Shares Outstanding: 126.88M
TypeInstitutionsShares
Increased
19
814.84K
New
20
3.06M
Decreased
15
716.90K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.69%
Pharmaceuticals & Medical Research
-1.48%
Key Executives
Chairman/Chief Executive Officer/Chief Scientific Officer/Director
Steve Hoffman
Chief Financial Officer/Chief Accounting Officer/Controller
Barbara Galaini
Chief Operating Officer
Michele Korfin
Other
Giuseppe Del Priore
Other
Jonathan Eckard
Secretary
James Biehl
Independent Director
David Carberry
Independent Director
Donald Degolyer
Independent Director
Douglas Michels
Independent Director
Gerald Sokol
Independent Director
Paul Sturman
Independent Director
Timothy Tyson
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About TYME
TYME Technologies, Inc. is a biotechnology company. The Company is focused on developing cancer metabolism-based therapies (CMBTsTM) for solid tumors and hematologic cancers. The Company’s lead clinical CMBT compound, SM-88, is an oral investigational modified tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells’ key defenses and leading to cell death through oxidative stress and exposure to the body’s natural immune system. SM-88 is an orally administered cancer metabolism-based therapy that is chemically altered to be non-functional for fundamental tumor cell processes, including protein synthesis. The Company has multiple cancer metabolism-based assets and other formulations for SM-88 in the pipeline, including injectable, intranasal, and transdermal that are expected to be advanced into the clinical setting.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Tyme Technologies Inc stock information, including NASDAQ:TYME real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TYME stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TYME stock methods without spending real money on the virtual paper trading platform.